EPIDEMIOLOGY AND OUTCOMES OF CHRONIC HEPATITIS B IN BRAZILIAN ADULTS: A NATIONWIDE ANALYSIS, 2010-2025
Author(s)
Igor C. Sampietri, MsC1, Rafael Aguiar Maciel, MsC2, Jucival Fernandes, PhD3, Juliana Domênico Queiroz, MsC4, Rodrigo Zilli, PhD3, Graziela Dalla Rosa Bernardino, MBA, MD5.
1Manager, GSK, São Paulo, Brazil, 2GSK, Porto Alegre, Brazil, 3GSK, Rio de Janeiro, Brazil, 4GSK, Niteroi, Brazil, 5GSK, São Paulo, Brazil.
1Manager, GSK, São Paulo, Brazil, 2GSK, Porto Alegre, Brazil, 3GSK, Rio de Janeiro, Brazil, 4GSK, Niteroi, Brazil, 5GSK, São Paulo, Brazil.
OBJECTIVES: This study aimed to describe the sociodemographic characteristics, diagnostic and treatment patterns, HBsAg positivity, and mortality associated with CHB among Brazilian adults.
METHODS: A retrospective descriptive analysis was conducted using separately secondary, publicly available national databases from the Brazilian Ministry of Health, including the Notifiable Diseases Information System (SINAN), the Medication Logistics Control System (SICLOM), and the Mortality Information System (SIM), covering the period from 2010 to 2025. Adults (≥18 years) were diagnosed with CHB (ICD-10 B18.0 or B18.1) included. Demographic and clinical data at diagnosis, treatment characteristics, and CHB-related deaths were analyzed using descriptive methods.
RESULTS: Between 2010-2023, SINAN reported 184.590 Brazilian were diagnosed with hepatitis B, of whom 75.8% (139.856) presented chronic hepatitis B (CHB), a proportion that remained stable over time. The mean age of CHB was 43 years. HIV coinfection occurred in approximately 5.0% of cases, while about 3.2% had hepatitis C coinfection, and 9.2% of diagnoses were identified during pregnancy. Diagnostic was performed in 99.6% of CHB patients by HBsAg qualitative testing, with 99.0% positivity, and 50.1% were tested for HBeAg, of whom 15.0% were reactive. According to SICLOM, 43.405 patients were under treatment in 2025, with an average annual increase of 5.567 new treatment initiations and most new patients were non-cirrhotic (74.6%). Tenofovir was the most frequently treatment in use in 2025 (50.0%), followed by entecavir and tenofovir alafenamide (45.6% and 4.2% respectively). Despite this, in average 10.547 patients interrupted treatment annually. From 2010 to 2024, SIM reported 6.875 deaths caused or associated with chronic hepatitis B were recorded, with 2.558 (37.2%), predominantly associated with cirrhosis.
CONCLUSIONS: Despite broad diagnostic coverage and expanding access to antiviral therapy, chronic hepatitis B in Brazil continues to result in significant mortality, largely driven by cirrhosis. Strengthening early diagnosis, continuous treatment, and long-term follow-up is critical to reducing CHB-related burden.
METHODS: A retrospective descriptive analysis was conducted using separately secondary, publicly available national databases from the Brazilian Ministry of Health, including the Notifiable Diseases Information System (SINAN), the Medication Logistics Control System (SICLOM), and the Mortality Information System (SIM), covering the period from 2010 to 2025. Adults (≥18 years) were diagnosed with CHB (ICD-10 B18.0 or B18.1) included. Demographic and clinical data at diagnosis, treatment characteristics, and CHB-related deaths were analyzed using descriptive methods.
RESULTS: Between 2010-2023, SINAN reported 184.590 Brazilian were diagnosed with hepatitis B, of whom 75.8% (139.856) presented chronic hepatitis B (CHB), a proportion that remained stable over time. The mean age of CHB was 43 years. HIV coinfection occurred in approximately 5.0% of cases, while about 3.2% had hepatitis C coinfection, and 9.2% of diagnoses were identified during pregnancy. Diagnostic was performed in 99.6% of CHB patients by HBsAg qualitative testing, with 99.0% positivity, and 50.1% were tested for HBeAg, of whom 15.0% were reactive. According to SICLOM, 43.405 patients were under treatment in 2025, with an average annual increase of 5.567 new treatment initiations and most new patients were non-cirrhotic (74.6%). Tenofovir was the most frequently treatment in use in 2025 (50.0%), followed by entecavir and tenofovir alafenamide (45.6% and 4.2% respectively). Despite this, in average 10.547 patients interrupted treatment annually. From 2010 to 2024, SIM reported 6.875 deaths caused or associated with chronic hepatitis B were recorded, with 2.558 (37.2%), predominantly associated with cirrhosis.
CONCLUSIONS: Despite broad diagnostic coverage and expanding access to antiviral therapy, chronic hepatitis B in Brazil continues to result in significant mortality, largely driven by cirrhosis. Strengthening early diagnosis, continuous treatment, and long-term follow-up is critical to reducing CHB-related burden.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH67
Topic
Epidemiology & Public Health
Disease
Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas